1. bookVolume 27 (2019): Issue 2 (April 2019)
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
access type Open Access

Seroprevalence and risk factors for hepatitis E virus infection in the Romanian adult population: a cross-sectional study in a tertiary hospital

Published Online: 02 May 2019
Page range: 199 - 208
Received: 24 Dec 2018
Accepted: 03 Mar 2019
Journal Details
License
Format
Journal
eISSN
2284-5623
First Published
08 Aug 2013
Publication timeframe
4 times per year
Languages
English
Abstract

Background: The primary goal was to estimate the seroprevalence of autochthonous hepatitis E virus (HEV) infection in adult Romanian population. Additionally, we aimed to identify the risk factors associated with the HEV seropositive status.

Methods: Between January 2015 and December 2016, 201 adult patients were tested for antiHEV-IgG. Multivariate logistic regression was used to examine for factors associated with a positive HEV-IgG test. The level of significance was set at α = 0.05.

Results: The final analysis included 175 patients who followed the study protocol. Forty-sex (26.3%) had positive, 121 (69.1%) had negative, and 8 (4.6%) had indeterminate antiHEV-IgG results. Patients with positive anti-HEV-IgG were older [median age: 54.5 years (IQR 43-65)] compared to patients with negative anti-HEV-IgG [median age: 37.5 years (IQR 28-57.5)], p <0.001. A positive HEV-IgG was more common in patients with history of blood transfusions [n=10 (22.7%) versus (vs) n=11 (9.4%), p=0.025], in those with immunosuppressive conditions [n=18 (40.9%) vs n=27 (23.1%), p=0.025] and in patients with positive hepatitis B surface antigen (HBsAg) [n=14 (31.1%) vs n=10 (10.3%), p=0.002].

Conclusions: In conclusion, we found that autochthonous HEV seropositivity is common in our study population, especially in older patients, previous blood transfusions, presence of immunosuppressive conditions, and positive HBsAg.

Keywords

1. Dalton HR, Kamar N, Baylis SA, Moradpour D, Wedemeyer H, Negro F. EASL Clinical Practice Guidelines on hepatitis E virus infection. J Hepatol. 2018;68:1256–71. DOI: 10.1016/j.jhep.2018.03.00510.1016/j.jhep.2018.03.005Open DOISearch in Google Scholar

2. Nimgaonkar I, Ding Q, Schwartz RE, Ploss A. Hepatitis E virus: advances and challenges. Nature Reviews Gastroenterology & Hepatology. 2018;15:96-110. DOI: 10.1038/nrgastro.2017.15010.1038/nrgastro.2017.150Open DOISearch in Google Scholar

3. Hepatitis E: a neglected virus. Editorial. The Lancet Gastroenterology & Hepatology. 2016;1(4):261. DOI: 10.1016/S2468-1253(16)30152-210.1016/S2468-1253(16)30152-2Open DOISearch in Google Scholar

4. Purdy MA, Harrison TJ, Jameel S, Meng XJ, Okamoto H, Van der Poel WHM, et al. ICTV virus taxonomy profile: hepeviridae. J Gen Virol. 2017;98:2645–6. DOI: 10.1099/jgv.0.00094010.1099/jgv.0.000940571825429022866Open DOISearch in Google Scholar

5. World Health Organization. Hepatitis E vaccine: WHO position paper, May 2015 – Recommendations. Vaccine. 2016;34(3):304-5. DOI: 10.1016/j.vaccine.2015.07.05610.1016/j.vaccine.2015.07.05626232546Open DOISearch in Google Scholar

6. Debing Y, Moradpour D, Neyts J, Gouttenoire J. Update on hepatitis E virology: Implications for clinical practice. J Hepatol. 2016;65(1):200-12. DOI: 10.1016/j.jhep.2016.02.04510.1016/j.jhep.2016.02.04526966047Open DOISearch in Google Scholar

7. Fischer C, Hofmann M, Danzer M, Hofer K, Kaar J, Gabriel C. Seroprevalence and Incidence of hepatitis E in Blood Donors in Upper Austria. PLoS ONE. 2015;10(3):e0119576. DOI: 10.1371/journal.pone.011957610.1371/journal.pone.0119576435362525751574Search in Google Scholar

8. Hartl J, Otto B, Madden RG, Webb G, Woolson KL, Kriston L, et al. Hepatitis E Seroprevalence in Europe: A Meta-Analysis. Viruses. 2016;8(8):211. DOI: 10.3390/v808021110.3390/v8080211499757327509518Search in Google Scholar

9. Slot E, Hogema B M, Riezebos-Brilman A, Kok T M, Molier M, Zaaijer H L. Silent hepatitis E virus infection in Dutch blood donors, 2011 to 2012. Euro Surveill. 2013;18(31). pii: 20550. DOI: 10.2807/1560-7917. ES2013.18.31.2055010.2807/1560-7917.ES2013.18.31.2055023929229Open DOISearch in Google Scholar

10. Adlhoch C, Avellon A, Baylis SA, Ciccaglione AR, Couturier E, de Sousa R, et al. Hepatitis E virus: Assessment of the epidemiological situation in humans in Europe, 2014/15. J Clin Virol. 2016;82:9–16. DOI: 10.1016/j.jcv.2016.06.01010.1016/j.jcv.2016.06.01027393938Search in Google Scholar

11. Hewitt PE, Ijaz S, Brailsford SR, Brett R, Dicks S, Haywood B, et al. Hepatitis E virus in blood components: a prevalence and transmission study in southeast England. Lancet. 2014;384:1766–73; DOI: 10.1016/S0140-6736(14)61034-510.1016/S0140-6736(14)61034-5Open DOISearch in Google Scholar

12. Kamar N, Wang W, Dalton HR, Pan Q. Direct-acting antiviral therapy for hepatitis E virus? The Lancet Gastroenterology & Hepatology. 2017;2(3):154–5; DOI: 10.1016/S2468-1253(16)30242-410.1016/S2468-1253(16)30242-4Open DOISearch in Google Scholar

13. World Health Organization. Hepatitis E vaccine: WHO position paper (Note de synthèse: position de l’OMS à propos du vaccine contre l’hépatite E). Weekly epidemiological record (Relevé épidémiologique hebdomadaire) 2015;90:185–200.Search in Google Scholar

14. Nascimento MSJ, Pereira SS, Teixeira J, Abreu-Silva J, Oliveira RMS, Myrmel M et al. A nationwide serosurvey of hepatitis E virus antibodies in the general population of Portugal. Eur J Public Health. 2018;28(4):720-4. DOI: 10.1093/eurpub/ckx21310.1093/eurpub/ckx21329237007Open DOISearch in Google Scholar

15. Aggarwal R, Gandhi S. The Global Prevalence of Hepatitis E Virus Infection and Susceptibility: A Systematic Review. Immunization, Vaccines and Biologicals. 2010; WHO/IVB/10.14.Search in Google Scholar

16. Mansuy JM, Bendall R, Legrand-Abravanel F, Sauné K, Miédouge M, Ellis V, et al. Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis. 2011;17:2309–12. DOI: 10.3201/eid1712.11037110.3201/eid1712.110371331120022172156Open DOISearch in Google Scholar

17. Muller B, Koch H, Pichl L. PCR-Screening of blood donations for hepatitis E with the cobas HEV test performed on the new Roche cobas 8800 platform in minipools of 6. Transfus Med Hemother. 2015;42:1–66.Search in Google Scholar

18. Zaaijer HL. No artifact, hepatitis E is emerging. Hepatology. 2015;62:654. DOI: 10.1002/hep.2761110.1002/hep.2761125418372Open DOISearch in Google Scholar

19. Thom K, Gilhooly P, McGowan K, Malloy K, Jarvis LM, Crossan C, et al. HEV in Scotland: evidence of recent increase in viral circulation in humans. Euro Surveill. 2018;23(12). DOI: 10.2807/1560-7917. ES.2018.23.12.17-0017410.2807/1560-7917.ES.2018.23.12.17-00174620525929589577Open DOISearch in Google Scholar

20. Domanović D, Tedder R, Blümel J, Zaaijer H, Gallian P, Niederhauser C, et al. Hepatitis E and blood donation safety in selected European countries: a shift to screening? Euro Surveill. 2017;22(16):30514. DOI: 10.2807/1560-7917.ES.2017.22.16.3051410.2807/1560-7917.ES.2017.22.16.30514540448028449730Open DOISearch in Google Scholar

21. Dreier J, Knabbe C, Vollmer T. Transfusion-Transmitted Hepatitis E: NAT Screening of Blood Donations and Infectious Dose. Frontiers in Medicine. 2018;5:5. DOI: 10.3389/fmed.2018.0000510.3389/fmed.2018.00005579928729450199Open DOISearch in Google Scholar

22. Spada E, Pupella S, Pisani G, Bruni R, Chionne P, Madonna E, et al. A nationwide retrospective study on prevalence of hepatitis E virus infection in Italian blood donors. Blood Transfusion. 2018;16(5):413-21.Search in Google Scholar

Recommended articles from Trend MD

Plan your remote conference with Sciendo